Leo Cancer Care has raised $65 million in Series D financing to scale its integrated upright cancer care platform, which is designed to image and treat patients in a seated position rather than the conventional lying-down setup. The oversubscribed round supports manufacturing scale-up, commercial deployment and continued development across upright proton therapy, photon therapy and
Proton therapy is precise but hard to scale. Mevion’s Naples win tests whether compact systems can shift access across Southern Europe.
Proton therapy has long had an infrastructure problem. Mevion’s S250-FIT asks whether existing LINAC vaults can change that.
UNC Health selects Mevion’s compact proton system. Discover what this means for proton therapy economics, workflows, and academic cancer care.
A new phase III clinical trial published in The Lancet has shown that proton therapy significantly improves overall survival and reduces treatment-related toxicities in patients with oropharyngeal cancers compared to traditional photon-based radiation. Conducted across 21 U.S. institutions and led by researchers at the University of Texas MD Anderson Cancer Center, the study is the